Leading science architect, Paul Dempsey, is to join Nightingale Associates as the new board-level Science Development Director this month.

Specialising in the pharmaceutical and science sector, Dempsey previously worked for CBRE, Pfizer and Bovis Lend Lease Pharmaceutical. His addition to Nightingale Associates, a leading architectural practice specialising in health, education and science buildings, aims to build upon the practice’s accomplishments within the science sector, helping to promote the company’s knowledge and innovation.

Dempsey said: “I am delighted to be joining Nightingale Associates to help further expand the excellent track record it already has in the science sector. My appointment is intended to boost the science capability with our existing clients and to help develop future work in new and exciting industry sectors.”

Dempsey was recognised as a pioneer and leader of ‘Lab of the Future’ projects, was awarded the prestigious William E Upjohn prize for innovation, and was the first non-scientist award winner in Pfizer’s history for his influential role on the Pfizer FlexiLab projects.

Starting in mid-September Dempsey will be based in Nightingale Associates’ London office.